References
- Bendtzen K. Cytokines and natural regulators of cytokines. Immunol. Lett. 1994; 43: 111–123
- Arend W. P. Interleukin-1 receptor antagonist. Adv. Immunol. 1993; 54: 167–227
- Poutsiaka D. D., Clark B. D., Vannier E., Dinarello C. A. Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood 1991; 78: 1275–1281
- Dinarello C. A. Is there a role for interleukin-1 blockade in intravenous immunoglobulin therapy?. Immunol. Rev. 1994; 139: 173–188
- Arend W. P., Leung D. Y. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol. Rev. 1994; 139: 71–78
- Arend W. P., Joslin F. G., Massoni R. J. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J. Immunol. 1985; 134: 3868–3875
- Schur P. H., Chang D. M., Baptiste P., Uhteg L. C., Hanson D. C. Human monocytes produce IL-1 and an inhibitor of IL-1 in response to two different signals. Clin. Immunol. Immunopathol. 1990; 57: 45–63
- Hansen M. B., Svenson M., Bendtzen K. Human anti-interleukin 1α antibodies. Immunol. Lett. 1991; 30: 133–140
- Herzyk D. J., Berger A. E., Allen J. N., Wewers M. D. Sandwich ELISA formats designed to detect 17 kDa IL-1β significantly underestimate 35 kDa IL-1β. J. Immunol. Methods. 1992; 148: 243–254
- Arend W. P., Smith M. F., Jr., Janson R. W., Joslin F. G. IL-1 receptor antagonist and IL-1β production in human monocytes are regulated differently. J. Immunol. 1991; 147: 1530–1536
- Marsh C. B., Pope H. A., Wewers M. D. Fc gamma receptor cross-linking down-regulates IL-1 receptor antagonist and induces IL-1 beta in mononuclear phagocytes stimulated with endotoxin or Staphylococcus aureus. J. Immunol. 1994; 152: 4604–4611
- Tilg H., Vannier E., Vachino G., Dinarello C. A., Mier J. W. Antiinflammatory properties of hepatic acute phase proteins: Preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1β synthesis by human peripheral blood mononuclear cells. J. Exp. Med. 1993; 178: 1629–1636
- Tilg H., Trehu E., Atkins M. B., Dinarello C. A., Mier J. W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83: 113–118
- Aukrust P., Froland S. S., Liabakk N. B., Mailer F., Nordoy I., Haug C., et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84: 2136–2143
- Svenson M., Hansen M. B., Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J. Clin. Invest. 1993; 92: 2533–2539
- Takei S., Arora Y. K., Walker S. M. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by Staphylococcal toxin superantigens. J. Clin. Invest. 1993; 91: 602–607
- Abe Y., Horiuchi A., Miyake M., Kimura S. Anticytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol. Rev. 1994; 139: 5–19
- Kazatchkine M. D., Dietrich G., Hurez V., Ronda N., Bellon B., Rossi F., et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig). Immunol. Rev. 1994; 139: 79–107
- Bendtzen K., Hansen M. B., Ross C., Poulsen L. K., Svenson M. Cytokines and autoantibodies to cytokines. Stem. Cells. 1995; 13: 206–222